| Metric | Value (₹ Cr) | vs Q4 FY25 |
|---|---|---|
| Revenue | 145.07 | 21.2% |
| Total Income | 147.75 | 21.0% |
| Expenditure | 100.34 | 18.4% |
| PBT | 47.41 | 26.0% |
| Net Profit | 34.79 | 30.9% |
| OPM | 35.64% | 1.07pp |
| NPM | 23.55% | 3.38pp |
| EPS | 4.32 | 31.3% |
Supriya Lifescience Ltd Reports Rs 145.07 Cr Revenue and 35.6% EBITDA Margin in Q1 FY26
14 Aug 2025 · 14 Aug 2025, 03:56 pm
Summary
Supriya Lifescience Ltd., a cGMP-compliant business with a strong track record in APl manufacturing and a focus on products from a variety of therapeutic segments, has reported its Q1 FY26 results with a 9.7% year-over-year decline in Revenue to Rs 145.07 crore compared to Rs 160.63 crore in Q1 FY25. The company's EBITDA stood at Rs. 51.70 crore, with an EBITDA margin of 35.6%, as against Rs 62.54 crore in Q1 FY25 with a margin of 38.9%. The Profit After Tax (PAT) for Q1 FY26 was Rs 34.79 crore, compared to RS 44.64 crore in Q1 FY25. The PAT Margin stood at 24.0% in Q1 FY26 versus 27.8% in Q1 FY25.
Key Highlights
- 1
9.7% year-over-year decline in Revenue to Rs 145.07 crore compared to Rs 160.63 crore in Q1 FY25
- 2
EBITDA for Q1 FY26 stood at Rs. 51.70 crore, with an EBITDA margin of 35.6%
- 3
Profit After Tax (PAT) for Q1 FY26 was Rs 34.79 crore
- 4
Anaesthetic segment led the revenue in Q1, contributing 53% to the revenue vs 45% in Q1 FY25
- 5
European markets now contribute 41% of our business revenue in Q1 FY26, up from 34% in Q1 FY25
- 6
Capacity Utilisation has recovered from 70% in FY25 to 76% in FY26
- 7
Three separate land parcels near different plants have been acquired to support future growth
Management Comments
Mr. Satish Wagh
Our Q1 results reflect a temporary impact from the delay in the production facility campaign due to essential repair and maintenance at our Lote facility. These upgrades were critical to improving the efficiency of our older blocks and enabling full utilisation of Module E for upcoming product launches. Despite the revenue dip, EBITDA margins remained strong at 36%, backed by improved backwards integration and increased contribution from regulated markets. With the Ambernath site progressing towards commercial production in Q4, a strong pipeline of 3—4 product launches in FY26, and healthy demand across key therapeutic areas, we expect the second half to recover the delays from H1. We remain on track to deliver ~20% growth and reach Rs 1,000 crore revenue by FY27.
Informational and educational content only. Not investment advice.